PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMavacamten
Camzyos(mavacamten)
Camzyos (mavacamten) is a small molecule pharmaceutical. Mavacamten was first approved as Camzyos on 2022-04-28. It has been approved in Europe to treat hypertrophic cardiomyopathy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Camzyos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mavacamten
Tradename
Company
Number
Date
Products
CAMZYOSBristol Myers SquibbN-214998 RX2022-04-28
4 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
camzyosNew Drug Application2024-04-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
MAVACAMTEN, CAMZYOS, BRISTOL
2029-04-28ODE-398
2027-04-28NCE
2026-06-15M-297
Patent Expiration
Patent
Expires
Flag
FDA Information
Mavacamten, Camzyos, Bristol
91812002034-06-19DS, DP
95858832034-06-19U-3373
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hypertrophic cardiomyopathyD002312EFO_0000538I42.12471821
CardiomyopathiesD009202EFO_0000318I422471821
HypertrophyD006984EFO_0002460—1471517
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333HP_0001635I50—1———1
Ventricular outflow obstructionD014694EFO_1001448——1———1
Left ventricular outflow obstructionD000092242———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———7————7
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy rateD018873——————11
Breast feedingD001942——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMavacamten
INNmavacamten
Description
Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.
Classification
Small molecule
Drug classallosteric cardiac myosin modulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
Identifiers
PDB—
CAS-ID1642288-47-8
RxCUI—
ChEMBL IDCHEMBL4297517
ChEBI ID—
PubChem CID117761397
DrugBankDB14921
UNII IDQX45B99R3J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Camzyos – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 720 documents
View more details
Safety
Black-box Warning
Black-box warning for: Camzyos
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,406 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use